Clinical Trial Update: A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update evaluating RC48-ADC in combination with JS001 for locally advanced or metastatic urothelial cancer across Phase 1 and Phase 2 to assess sa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• JS001 (PD-1 inhibitor)
• RC48-ADC (Disitamab Vedotin)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: Urothelial Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN